<DOC>
	<DOC>NCT02472977</DOC>
	<brief_summary>The purpose of this study is to determine whether the combination of Ulocuplumab and Nivolumab is safe and effective in the treatment of pancreatic cancer and small cell lung cancer.</brief_summary>
	<brief_title>Safety and Efficacy Study of Ulocuplumab and Nivolumab in Subjects With Solid Tumors</brief_title>
	<detailed_description>- Intervention model: Single group for Stage 1 DLT, then Parallel - Data Monitoring Committee: No (Stage 1) Yes (Stage 2 Randomized Ph2)</detailed_description>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com SCLC or PAC that is advanced or has spread to other parts of the body Treated with at least one other chemotherapy that did not work or where cancer relapsed Minimal limitations on activities of daily living as measured by Eastern Cooperative Oncology Group (ECOG) score of 01 Patients with cancer that spread to the brain Active, known or suspected autoimmune disease Prior treatment with any drug that targets T cell costimulation pathways (such as checkpoint inhibitors)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>